Journal article · 2025 · Open access

The transforming role of wharton’s jelly mesenchymal stem cell-derived exosomes for diabetic foot ulcer healing: a randomized controlled clinical trial

Mohamed S. Kishta, A. M. Hafez, Tamer Hydara, Zeinab Hamed, Mohamed M. Bahr, Ashraf Shamaa, Ahmed N. Abdallah

Stem Cell Research & Therapy, 16(1), 559 · Published 13 October 2025 · DOI 10.1186/s13287-025-04690-y

Open PDFView at the publisherCite this paper

In brief

“The transforming role of wharton’s jelly mesenchymal stem cell-derived exosomes for diabetic foot ulcer healing: a randomized controlled clinical trial” is a 2025 journal article by Mohamed S. Kishta and 6 co-authors, published in Stem Cell Research & Therapy. OpenAlex counts 67 citations as of 19 November 2026, which puts it in the top 4% of works published in 2025 by citations. It is open access under a CC BY licence: the full text is free to read at Stem Cell Research & Therapy.

Citations
67
Most cited in
2026 (63)
Field-weighted impact
40.18
References
57
Authors
7

Abstract

BACKGROUND: Diabetic foot ulcers (DFUs), which have high rates of recurrence, amputation, and death, are a significant complication in the therapy of diabetes. Chronic inflammation, vascular dysfunction, and peripheral neuropathy are the results of their etiology, which includes dysregulated glucose homeostasis. These elements contribute to the poor clinical outcomes of DFUs and their complexity. Exosomes, which are natural nanovesicles that promote intercellular communication by transporting functional molecular cargos such as proteins, lipids, and nucleic acids, are being investigated as novel treatment approaches for diabetic foot ulcers (DFUs). These exosomes present a viable therapy option for DFU because they can alter cellular functions and promote wound healing. METHODS: To improve wound healing in patients with diabetic foot ulcers (DFUs), we assessed the safety and effectiveness of Wharton's jelly-derived mesenchymal stem cell (WJ-MSC) exosomes in this study. 110 individuals with persistent DFUs participated in our research. Three groups were randomly selected from among the participants. For 4 weeks, the first group got weekly topical application of WJ-MSC exosome along with standard of care (SOC); the second control group received SOC alone; and the third placebo group received SOC together with CMC (the exosome vehicle). While effectiveness outcomes comprised the rate of wound closure and the duration to full epithelialization, safety endpoints included the frequency of adverse events. RESULTS: According to our study's findings, 53 patients (62%) had fully recovered by the end of the study, and the treated group had a significantly higher percentage of patients who had fully recovered than the control group. The treated group's mean time to fully recover was 6 weeks (range: 4-8 weeks), while the controls were 20 weeks (range: 12-28 weeks). CONCLUSIONS: Our research proved that MSC-Exos is a viable treatment option for DFUs. MSC-Exos provide a multimodal approach to improve wound healing outcomes in diabetes patients.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Kishta, M. S., Hafez, A. M., Hydara, T., Hamed, Z., Bahr, M. M., Shamaa, A., & Abdallah, A. N. (2025). The transforming role of wharton’s jelly mesenchymal stem cell-derived exosomes for diabetic foot ulcer healing: a randomized controlled clinical trial. Stem Cell Research & Therapy, 16(1), 559. https://doi.org/10.1186/s13287-025-04690-y

MLA 9

Kishta, Mohamed S., et al. “The transforming role of wharton’s jelly mesenchymal stem cell-derived exosomes for diabetic foot ulcer healing: a randomized controlled clinical trial.” Stem Cell Research & Therapy, vol. 16, no. 1, 2025, p. 559. https://doi.org/10.1186/s13287-025-04690-y.

Chicago

Kishta, Mohamed S., A. M. Hafez, Tamer Hydara, Zeinab Hamed, Mohamed M. Bahr, Ashraf Shamaa, and Ahmed N. Abdallah. 2025. “The transforming role of wharton’s jelly mesenchymal stem cell-derived exosomes for diabetic foot ulcer healing: a randomized controlled clinical trial.” Stem Cell Research & Therapy 16 (1): 559. https://doi.org/10.1186/s13287-025-04690-y.

Harvard

Kishta, M. S. et al. (2025) ‘The transforming role of wharton’s jelly mesenchymal stem cell-derived exosomes for diabetic foot ulcer healing: a randomized controlled clinical trial’, Stem Cell Research & Therapy, 16(1), p. 559. doi:10.1186/s13287-025-04690-y.

IEEE

M. S. Kishta et al., “The transforming role of wharton’s jelly mesenchymal stem cell-derived exosomes for diabetic foot ulcer healing: a randomized controlled clinical trial,” Stem Cell Research & Therapy, vol. 16, no. 1, p. 559, 2025, doi: 10.1186/s13287-025-04690-y.

BibTeX

@article{kishta2025transforming,
  title     = {{The transforming role of wharton’s jelly mesenchymal stem cell-derived exosomes for diabetic foot ulcer healing: a randomized controlled clinical trial}},
  author    = {Kishta, Mohamed S. and Hafez, A. M. and Hydara, Tamer and Hamed, Zeinab and Bahr, Mohamed M. and Shamaa, Ashraf and Abdallah, Ahmed N.},
  journal   = {Stem Cell Research \& Therapy},
  year      = {2025},
  volume    = {16},
  number    = {1},
  pages     = {559},
  doi       = {10.1186/s13287-025-04690-y},
  url       = {https://doi.org/10.1186/s13287-025-04690-y}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Surgery › Wound Healing and Treatments

  • diabetic foot ulcer
  • Wharton's jelly mesenchymal stem cells
  • exosomes
  • wound healing
  • re-epithelialization
  • nanovesicles
  • diabetes complications

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Kishta, M. S., Hafez, A. M., Hydara, T., Hamed, Z., Bahr, M. M., Shamaa, A., & Abdallah, A. N. (2025). The transforming role of wharton’s jelly mesenchymal stem cell-derived exosomes for diabetic foot ulcer healing: a randomized controlled clinical trial. Stem Cell Research & Therapy, 16(1), 559. https://doi.org/10.1186/s13287-025-04690-y

How many times has this paper been cited?

67 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Stem Cell Research & Therapy: sign in and open the PDF from this page.

Who wrote this paper?

Mohamed S. Kishta, A. M. Hafez, Tamer Hydara, Zeinab Hamed, Mohamed M. Bahr, Ashraf Shamaa, Ahmed N. Abdallah.

What is the DOI of this paper?

10.1186/s13287-025-04690-y, permanently at https://doi.org/10.1186/s13287-025-04690-y. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.